Compare Merck & Co., Inc. (MRK) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Ralph Lauren Corp — how do they compare? Merck & Co., Inc. trades at $131.94 (market cap $321.77B), while Ralph Lauren Corp trades at $395.94 (market cap $23.70B). The key difference: Merck & Co., Inc. is far larger — about 13.6× Ralph Lauren Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | RL | |
|---|---|---|
Market Cap | $321.77B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $131.84 | $414.25 |
52-Week Low | $77.60 | $285.35 |
Enterprise Value | $368.53B | $24.76B |
Dividend Yield | 2.61% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Ralph Lauren (RL) trades at $406.89, up 2.87% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support near $396 and resistance at $413. Fundamentals are robust, with Q2 2026 EPS of $4.59 beating estimates, revenue growth to $7.08B in 2025, and high profitability margins. Analyst sentiment is overwhelmingly positive, with 66% recommending Buy and a consensus price target of $456.50.
The outlook remains favorable due to brand strength and margin expansion, but risks include economic sensitivity and high valuation multiples. Near-term catalysts hinge on Q3 2026 earnings due soon. The stock's proximity to its 52-week high suggests cautious entry points may be optimal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
